Just published: AI Scoring System for Histology Review in Ulcerative Colitis

Just published: AI Scoring System for Histology Review in Ulcerative Colitis

An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis

IAG, Takeda and scientific collaborators just published validation article for the novel AI powered approach to assess histopathology slides in Ulcerative Colitis

This study aimed to investigate whether an artificial intelligence (AI) system developed using image processing and machine learning algorithms could measure histological disease activity based on the Nancy index.

A total of 200 histological images of patients with UC were used in this study. A novel AI algorithm was developed using state-of-the-art image processing and machine learning algorithms based on deep learning and feature extraction. The cell regions of each image, followed by the Nancy index, were manually annotated and measured independently by four histopathologists. Manual and AI-automated measurements of the Nancy index score were conducted and assessed using the intraclass correlation coefficient (ICC).

Validation work of AI vs expert pathologists: Intraclass correlation coefficient statistical analyses were performed to evaluate the AI tool and used as a reference to calculate the accuracy. The average ICC among the histopathologists was 89.3 and the average ICC between histopathologists and the AI tool was 87.2. The AI tool was found to be highly correlated with histopathologists.

The high correlation of performance of the AI method suggests promising potential for inflammatory bowel disease clinical applications. A standardized automated histological AI-driven scoring system can potentially be used in daily inflammatory bowel disease practice to reduce training needs and resource use, eliminate the subjectivity of the pathologists, and assess disease severity for treatment decisions.

‘AI-based methods demonstrate feasibility, reliability and validity when utilized to quantify UC slides. Computer-aided evaluation could be considered as an alternative to conventional expert driven methods especially when it comes to pathology slide reviews in clinical research or practice,’ said Dr Olga Kubassova, IAG’s President.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Join Dr Olga Kubassova, IAG’s President and our collaborators at Digestive Disease Week annual meeting, Washington, 18-21 May 2024.

We continue work on “An Artificial Intelligence driven scoring system to measure histological disease activity in Ulcerative Colitis”

The full manuscript was recently released: ‘An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis’, United European Gastroenterol J, 2024 Apr 8.,  doi: 10.1002/ueg2.12562. https://pubmed.ncbi.nlm.nih.gov/38590110/ 

At DDW, IAG’s team are meeting with investigators involved into this collaboration on the application of IAG’s Artificial Intelligence (AI) driven assessment of histopathology ulcerative colitis images (supported by Takeda).

Schedule a meeting: imaging.experts@ia-grp.com

About the project

The collaboration is supported by prominent clinical centres and opinion leaders, including sites in Switzerland, France, Canada, USA, Israel,  Portugal, Brazil, Canada and many other countries.

IAG and Takeda have been working together since 2019 and have developed a novel Artificial Intelligence (AI)-powered method for the assessment of histopathology ulcerative colitis images. The tool will potentially allow practising gastroenterologists to evaluate disease activity with an automated method that is accurate, reproducible and reliable in UC patients. To date, the AI Tool has been trained and tested on 200 images, showing performance comparable to a human expert. As the next step, the partners are engaging eight world-leading sites, who will test the AI Tool in their clinical practices.

Together with our commercial and academic partners, we are excited to be in the position to advance clinical decision-making by bringing better technologies into the play, said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

‘Augmenting clinical decision-making with AI in the field of histopathology has the potential to bring great value for management of patients with ulcerative colitis.  Our AI Tool’s ability to provide additional information on the disease state and patient response to a new treatment in real-time gives us ability to gain more insights and make better and faster decisions,’ said Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy.

As part of our 30-year commitment to gastroenterology, we recognize the importance of collaborations with digital health leaders, such as IAG, to identify and pursue cutting edge technologies to advance the care of patients.  We see great potential in this initiative and are excited to enter into the next phase of research using deep learning models and AI to support gastroenterologists’ in their patient care”, said Dr. Shashi Adsul, Sr. Director, Global Medical Unit Head at Takeda Pharmaceuticals International AG.

About DDW

Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: www.ia-grp.com 
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Announce Partnership

Image Analysis Group and Ferring Pharmaceuticals aim to advance Women’s Reproductive Health through AI-driven medical image analysis.

London, UK – 31 October 2023  – IAG, Image Analysis Group, an innovative medical imaging company, announce collaboration with Ferring Pharmaceuticals, to use Artificial Intelligence (AI)-driven medical image analysis to advance women’s reproductive health, by unveiling hidden patterns and relationships within data that elude human observation.

“The collaboration with IAG exemplifies our dedication to AI-driven research and development in the intricate realm of pregnancy”, says Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals.

 Dr. Olga Kubassova, CEO of IAG, commented:

“It is our pleasure to support the Ferring team. Together, our objective is to harness AI to reveal deeper insights into women’s reproductive health and bring the joy of delivering a healthy baby to women around the world.”

At IAG, we are committed to helping pharmaceutical partners to efficiently develop novel life-changing medicines, by leveraging our expertise in medical imaging and AI. The partners will utilize the power of IAG’s proprietary platform DYNAMIKA, developed to maximize efficiencies of handling large volumes of imaging data in multi-centre trials or across multiple trials and its integrated AI modules. This partnership holds the potential to bring innovative approaches to support women worldwide.

About IAG, Image Analysis Group 

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models. For more information, visit wp1.ia-grp.com.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Join IAG’s Expert Team at EULAR 2023: Novel ideas for drug development

Join IAG's Expert Team at EULAR 2023: Novel ideas for drug development

Join IAG’s Expert Team at EULAR 2023: Novel ideas for drug development

IAG is pleased to announce several publications at the upcoming EULAR 2023 conference. These publications represent IAG’s ongoing commitment to advancing the field of rheumatology through innovative research and collaboration. Join our team and collaborators who will be discussing the value of novel scoring system to improve clinical trials’ outcomes.

“Today, clinical trials require designs and endpoints which can give quick definitive answers about novel treatments in smaller patient cohorts and allow determining competitive edge of a novel drug candidate,” said Olga Kubassova, CEO and co-founder of IAG. “This is a great opportunity to showcase our research and support biotech and pharma collaborators.”

Below is a list of posters and presentations:

  • MRI Digital Artery Volume Index (DAVIX©) as quantitative, continuous imaging outcome measure of vascular disease in systemic sclerosis – Poster: POS1336

 

  • Efficacy of Apremilast on Whole-Body Inflammation Indices in Patients With Psoriatic Arthritis: Assessments by Whole-Body Magnetic Resonance Imaging in the Phase 4 MOSAIC Study – Publication: AB1535

 

  • Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study – Poster: POS0226

 

  • A Proof of Biological Concept Trial of CM101 to Target CCL24 in Systemic Sclerosis: a Biomarker Informed, Precision Medicine Approach – Publication: AB0808

 

  • A Phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in subjects with symptomatic knee osteoarthritis – Poster: POS0104

 

  • Five-Year Follow-Up Of A 2-Year Mri Treat-To-Target Strategy On Radiographic Damage Progression In Rheumatoid Arthritis Patients In Clinical Remission – The Imagine-More Study – Poster: POS0052

 

  • Intra-Articular Mm-Ii, A Novel Suspension Of Large Empty Multilamellar Liposomes, In Painful Knee Osteoarthritis: A 26 Week Phase 2b Randomized Trial – Poster: POS0106

 

  • The Influence Of Baseline Demographics On Variability Of Oa Pain Assessed By Womac Pain Change From Baseline In Interventional Trials – Poster:POS1361

 

  • Colchicine Twice Daily For Hand Osteoarthritis: Results From The Double-Blind, Randomised, Placebo-Controlled Color Trial – Presentation: OP0073 

 

  • 2023 Update Of Eular Recommendations For The Treatment Of Systemic Sclerosis – Presentation: OP0234

We will provide further updates on the specific details of these publications as they become available.

“It is important to us that our work is accessible to the broader scientific community,” said Prof. Mikael Boesen, chair of Scientific Advisory Board of IAG.

IAG looks forward to participating in EULAR 2023 and contributing to the ongoing advancement of the field of rheumatology.

Join IAG’s scientific team at EULAR 2023, May 30 – June 2 2023, Milan, Italy, at our poster presentations!

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Kubassova joins Fast Growth Icons & Female Founders Reception

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins the invitation-only network for founders & CEOs of the most successful fast growing scaleups, the Fast Growth Icons, London, 25th May 2023 and the Female Founders reception on the 24th May at Eight Club Moorgate.

Dr Kubassova is the CEO and Founder of IAG, investment professional in Biocapital Impact Fund and Analytics Ventures and scientist. She founded IAG, Image Analysis Group in 2007, straight after her PhD in Computer Science, and grew it into a global multi-million revenue organization, with headquarters in London, UK and offices in Philadelphia, USA and Hyderabad, India. Today, IAG has just under 100 full time staff, delivered over 400 global trials and pioneered use of Artificial Intelligence powered methods in drug development.

IAG’ team built many last partnerships and scientific collaborations with pharmaceutical, biotech and medtech companies and closely works with over 500 global clinical academic institutions.

‘It started with an idea that the world of drug development can benefit from novel technological advances, AI and digital infrastructure. Today, IAG helps to accelerate drug development and lower investment risks by using our proprietary platform DYNAMIKA, modern trial infrastructure and AI. We run imaging part of clinical trials, ensure the speed and cost-effectiveness, while delivering true insights about novel mechanisms of action and patients’ response, in real-time.’

IAG’s management team has ambitious growth plans and planning to create a high-impact, sustainable and fearlessly innovative company.

Fast Growth Icon’s mission is ‘creating the 100m+ revenue stars of the future. Fast Growth Icons provides the three pivotal things you need to deliver a breakout success Motivation – Inspirational founders share their success and failure stories and prepare you for the realities of being a founder of a business valued over $1b; Knowledge – Open dialogue amongst peers about the issues that matter, our guests consistently feedback being blown away by the quality of discussion and energy in the room; Connections – everyone is the founder of CEO of an impressive scaleup because a strong network and knowing who to get help from is key to fast-tracking growth.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins Rothschild’s Healthcare Dinner the National Gallery

Dr Kubassova joins Rothschild's Healthcare Dinner the National Gallery

Dr Kubassova joins Rothschild’s Healthcare Dinner the National Gallery

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins Rothschild’s Healthcare Dinner the National Gallery, London, UK, 26th May 2023.

Dr Kubassova, is the CEO and Founder of IAG, investment professional and scientist. She is a mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital raising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.

 

About Rothchild and Co

Rothschild & Co is a multinational investment bank and financial services company, and the flagship of the Rothschild banking group controlled by the French and British branches of the Rothschild family. They are a leading global financial services group, with seven generations of family control and a history of over 200 years at the centre of the world’s financial markets.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

IAG and AltruBio Partner to Deploy IAG’s AI methods in GI

IAG and AltruBio Partner to Deploy IAG's AI methods in GI

IAG and AltruBio Partner to Deploy IAG’s AI methods in GI

SAN FRANCISCO, May 08, 2023 – AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company specializing in the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced a joint poster presentation with their partner Image Analysis Group (IAG) at the Digestive Disease Week® conference, held at McCormick Place in Chicago, IL, from May 6-9, 2023.

David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will present proof of concept data utilizing a novel AI-powered method developed by IAG for the analysis of patient tissue from AltruBio’s Phase 2b open label study of immune checkpoint enhancer (ICE) ALTB-168, in patients with moderately to severely active anti-TNFα and/or anti-integrin refractory ulcerative colitis (UC).

“Using AI tools for histology simplifies the interpretation of histological samples and offers promise in establishing a new gold standard of histological assessment in clinical trials, as well as providing earlier signals for interpretation beneficial to both patients and scientists,” said Dr. Rubin.

Jesse Hall, M.D., Chief Medical Officer of AltruBio, added,

“IAG’s AI-powered technology accurately supports histological assessment of treatment response to our ICE in development. We plan to continue clinical validation of targeting PSGL-1 to treat autoimmune and inflammatory diseases and share further progress this year.”

Key data highlights include an 87% correlation between AI Tool-determined Nancy Indices and those conducted by an expert pathologist. The AI Tool also demonstrated a 93% decrease in automatically detected neutrophils for subjects who achieved clinical remission.

Poster Presentation Details:

Session Title: AGA IBD: Disease Activity Assessment Session Date & Time: May 8, 2023 from 12:30 PM to 1:30 PM CDT (UTC –5) Presentation Title: A Novel AI Tool is Accurate at Interpreting Histology and Detects Response to ALTB-168 Therapy in Patients with Moderate to Severe Ulcerative Colitis: Proof of Concept

About AltruBio Inc.

AltruBio is a privately held biotechnology company headquartered in San Francisco that focuses on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. Its first-generation molecule, ALTB-168, has achieved proof of mechanism in four autoimmune and inflammatory diseases. The next-generation ICE, ALTB-268, is currently being evaluated in a Phase 1 clinical trial.

About Digestive Disease Week Digestive Disease Week®

DDW is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Kubassova joins OMERACT meeting, Colorado Springs, May 2023

Dr Olga Kubassova, CEO of IAG, Image Analysis Group joins OMERACT meeting in Colorado Springs, Denver, 1-5 May 2023.

OMERACT is a global, volunteer-driven not for profit organization committed to improving outcomes for patients with autoimmune and musculoskeletal diseases through advancing the design and quality of clinical studies.

Dr Kubassova will be involved into sessions dedicated to the development of Core Outcome Sets (COS), identifying patient and disease-relevant to be measured and the corresponding measurements instruments for use in clinical trials and for regulatory approval.

This meeting is a critical event to the community and attended by the world-class domain experts, clinicians and the industry representatives to collaboratively define the state of the art outcome measures that can advance immunology research.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Join IAG’s Expert Team at Digestive Disease Week 2023

Join IAG's Expert Team at Digestive Disease Week 2023

Join IAG’s Expert Team at Digestive Disease Week 2023

At the DDW next week, IAG’s team will join the discussions about the value of pathology in Ulcerative Colitis and its ability to predict the disease severity and outcomes.

Our 2 presentations, with scientific and industry collaborators cover real-world AI deployment for gastroenterology clinical research and predictive nature of AI Histology in drug development.

IAG, Image Analysis Group, a leader in the field of IA and quantitative imaging for drug development, working across many therapeutic areas.

We deploy AI, our platform DYNAMIKA and global operations to extract meaningful insights from the imaging in clinical trials. We support phase 1-3 trials and special data mining projects, working in partnership with biotech and pharma companies. Examples and case studies of our work are available here: wp1.ia-grp.com

 

IAG’s team and collaborators will present 2 posters at Digestive Disease Week 2023 (DDW2023)

1: DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES –  Session date: May 7, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with Takeda Pharmaceuticals and a global panel of gastroenterology and pathology experts support the deployment of AI in gastroenterology practice. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting dataset generated over 43,000 characterisations that were used to further train the AI Tool in the segmentation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.

2: A NOVEL AI TOOL IS ACCURATE AT INTERPRETING HISTOLOGY AND DETECTS RESPONSE TO NEIHULIZUMAB THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: PROOF OF CONCEPT – Session date: May 8, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with AltruBio Inc and David T. Rubin MD, report in this abstract the conduct an AI driven retrospective analysis of digitised histology biopsy slides from AltruBio’s Phase IIb study of Neihulizumab (NCT03298022), a novel immune checkpoint agonistic antibody that binds to human CD162 that is being tested in UC and graft versus host disease. Quantitative analyses of cell and tissue types were performed longitudinally at screening and week 12 after 10 doses of Neihulizumab. Results reveal a correlation between disease remission and reduced neutrophil density. AI generated disease stage scores reported using the Nancy Index correlated well (87%) with human readers of the same biopsies.


Join IAG’s scientific team at DDW 2023, March 6-9 2023, Chicago, USA, at our poster presentations!

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

IAG are attending Digestive Disease Week 2023 to bring more AI into GI!

IAG are attending Digestive Disease Week 2023 to bring more AI into GI!

IAG are attending Digestive Disease Week 2023 to bring more AI into GI!

IAG’s team and collaborators will present 2 posters at Digestive Disease Week 2023 (DDW2023)

1: DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES –  Session date: May 7, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with Takeda Pharmaceuticals and a global panel of gastroenterology and pathology experts support the deployment of AI in gastroenterology practice. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting dataset generated over 43,000 characterisations that were used to further train the AI Tool in the segmentation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.

2: A NOVEL AI TOOL IS ACCURATE AT INTERPRETING HISTOLOGY AND DETECTS RESPONSE TO NEIHULIZUMAB THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: PROOF OF CONCEPT – Session date: May 8, 2023;  Session Time: 12:30 PM to 1:30 PM CDT

IAG‘s team together with AltruBio Inc and David T. Rubin MD, report in this abstract the conduct an AI driven retrospective analysis of digitised histology biopsy slides from AltruBio’s Phase IIb study of Neihulizumab (NCT03298022), a novel immune checkpoint agonistic antibody that binds to human CD162 that is being tested in UC and graft versus host disease. Quantitative analyses of cell and tissue types were performed longitudinally at screening and week 12 after 10 doses of Neihulizumab. Results reveal a correlation between disease remission and reduced neutrophil density. AI generated disease stage scores reported using the Nancy Index correlated well (87%) with human readers of the same biopsies.


“IAG are pleased to collaborate with world recognised opinion leaders to leverage IAG’s advanced imaging capabilities as we study the potential of AI driven histology to benefit patients with Ulcerative Colitis,” said Dr Olga Kubassova, CEO of IAG, Image Analysis Group.

Join IAG’s scientific team at DDW 2023, March 6-9 2023, Chicago, USA, at our poster presentations!

Mucosal healing is an established treatment target in UC, but not all clinical sites have access to the required resources. The AI Tool has the potential to facilitate rapid, detailed histological assessment in a clinical setting for the benefit of all UC patients” said Simon Hart, Director, Biopartnering, Image Analysis Group.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events